Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E, Mai E, Young J, Johnson C, Huseni M, Wang X, Chen Y, Wang P, Wang H, Dybdal N, Chu YW, Chiorazzi N, Scheer JM, Junttila T, Totpal K, Dennis MS, Ebens AJ. Sun LL, et al. Among authors: scheer jm. Sci Transl Med. 2015 May 13;7(287):287ra70. doi: 10.1126/scitranslmed.aaa4802. Sci Transl Med. 2015. PMID: 25972002
Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.
Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, Wang BE, Li Y, Mathieu M, Li G, Young J, Luis E, Lewis Phillips G, Stefanich E, Spiess C, Polson A, Irving B, Scheer JM, Junttila MR, Dennis MS, Kelley R, Totpal K, Ebens A. Junttila TT, et al. Among authors: scheer jm. Cancer Res. 2014 Oct 1;74(19):5561-71. doi: 10.1158/0008-5472.CAN-13-3622-T. Epub 2014 Sep 16. Cancer Res. 2014. PMID: 25228655
Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.
Spiess C, Bevers J 3rd, Jackman J, Chiang N, Nakamura G, Dillon M, Liu H, Molina P, Elliott JM, Shatz W, Scheer JM, Giese G, Persson J, Zhang Y, Dennis MS, Giulianotti J, Gupta P, Reilly D, Palma E, Wang J, Stefanich E, Scheerens H, Fuh G, Wu LC. Spiess C, et al. Among authors: scheer jm. J Biol Chem. 2013 Sep 13;288(37):26583-93. doi: 10.1074/jbc.M113.480483. Epub 2013 Jul 23. J Biol Chem. 2013. PMID: 23880771 Free PMC article.
Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling.
Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, Lee WP, Zhang J, Sharma N, Lu Y, Iyer S, Shields RL, Chiang N, Bauer MC, Wadley D, Roose-Girma M, Vandlen R, Yansura DG, Wu Y, Wu LC. Jackman J, et al. Among authors: scheer jm. J Biol Chem. 2010 Jul 2;285(27):20850-9. doi: 10.1074/jbc.M110.113910. Epub 2010 May 5. J Biol Chem. 2010. PMID: 20444694 Free PMC article.
Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye.
Tesar D, Luoma J, Wyatt EA, Shi C, Shatz W, Hass PE, Mathieu M, Yi L, Corn JE, Maass KF, Wang K, Dion MZ, Andersen N, Loyet KM, van Lookeren Campagne M, Rajagopal K, Dickmann L, Scheer JM, Kelley RF. Tesar D, et al. Among authors: scheer jm. MAbs. 2017 Nov/Dec;9(8):1297-1305. doi: 10.1080/19420862.2017.1372078. Epub 2017 Aug 30. MAbs. 2017. PMID: 28854082 Free PMC article.
43 results